Atlas Trials

Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults

Clinical trial NCT05266456 · COMPLETED

Trial details

NCT number
NCT05266456
Sponsor
Vaxcyte, Inc.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Pneumococcal Vaccines
Start date
2022-02-22
Primary completion
2023-01-10
Enrollment
835

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.